On the evening of January 29, New Milestone Health Technology Group Co., Ltd. (hereinafter referred to as "New Milestone", 002219SZ) announced its 2023 annual results. The net profit attributable to shareholders of listed companies in 2023 is expected to be 25 million yuan to 35 million yuan, a decrease of 84% to 78% over the same period last year; It is estimated that the net profit after deducting non-recurring gains and losses will be 20 million yuan to 30 million yuan, a decrease of 78% to 67% over the same period last year.
Source|New mileage official website).
New mileage said that during the reporting period, the company granted restricted ** to employees, and the above-mentioned net profit attributable to shareholders of listed companies and non-net profit forecast included the amortization of equity incentive expenses. Excluding the impact of amortization of equity incentive expenses, the company's operating net profit attributable to shareholders of listed companies is about 1$8.5 billion to $19.5 billion yuan, a year-on-year increase of about 19% to 25%; Net operating profit after deducting non-recurring gains and losses was approximately 18 billion to 19 billion yuan, a year-on-year increase of about 97% to 108%.
In 2023, New Milestone will strictly follow the sustainable development strategy in the two major sectors of medical services and pharmaceutical manufacturing, pay close attention to the achievement of budgets, continue to reduce costs and increase efficiency, and optimize the debt structure. In the medical service sector, the hospitals under the group firmly promoted the "1+N" strategy of "one general hospital + multiple specialty branches", the east branch of Siyang Hospital was opened, the new hospital area of Chongzhou Second Hospital was capped, the cancer campus of Xuyi County Hospital of Traditional Chinese Medicine (Xuyi Hengshan Cancer Hospital) was started, and the new hospital area of Wafangdian Third Hospital was launched, continuing to expand the regional medical market share; Continue to promote the construction of disciplines, and add a number of provincial and municipal key disciplines; Continuously enhance the teaching and scientific research strength of the hospital, Xuyi County Hospital of Traditional Chinese Medicine has become the clinical school of Yangzhou University School of Medicine, and formed a cooperation unit with Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine in the north-south cooperation project determined by Jiangsu Province, and Siyang Hospital and the Affiliated Hospital of Jiangsu University signed a pairing assistance agreement with the goal of building a regional medical center.
In the pharmaceutical sector, the new milestone focuses on the strategy of "pharmaceutical + consumption", and acquires Foren Pharmaceutical to form the whole industry chain business of traditional Chinese medicine; Duyiwei daily chemical products were officially put into the market, and business channels and market brands were built. The operating income of the pharmaceutical sector increased significantly year-on-year.
At the level of group management and control, New Milestone urged all operating entities to promote high-quality development strategies, continuously reduce costs through centralized procurement, reasonably control sales expenses through business structure adjustment, and reduce financial expenses through the optimization of debt structure, achieving a year-on-year increase in operating net profit.
According to the 2023 semi-annual report, medical services and pharmaceutical manufacturing are the core businesses of New Milestone. In terms of medical service business, New Milestone promotes the layout of medical institutions with regional medical centers as the strategy, creates a "1+N" innovative service model based on a tertiary general hospital and "general hospital + specialist branch", and builds a leading medical institution in the region, focusing on oncology, cardiovascular, cerebrovascular, orthopedic and other geriatric diseases. In terms of pharmaceutical manufacturing business, New Milestone has been committed to the research and development, production and sales of drugs for more than 20 years, and has a number of leading products in the field of Chinese patent medicine.
In the first half of 2023, the new mileage achieved an operating income of 160.7 billion yuan, an increase of 560%；The net profit attributable to shareholders of the listed company was 5700460,000 yuan, an increase of 1315%。
Jiupai financial reporter Huang Mengqi.
*: Jiupai News].
Statement: The copyright of this article belongs to the original author, if there is a mistake or infringement of your legitimate rights and interests, you can contact us by email, and we will deal with it in a timely manner. E-mail address: [email protected]